The EMA, FDA, and US EPA are looking to reduce unnecessary animal testing, which involves replacing in vivo animal studies with in vitro and in silico methods to determine the toxicity of a substance.
SAXOCON welcomes this focus on enhancing animal well-being while maintaining high standards for determining the safety of chemical compounds. These new methods are the future of toxicological risk assessment, a future that we have been at the forefront of for over 8 years.
Future-proof your development processes with our cutting-edge modelling and let our experts guide you to the best strategy for using New Approach Methodologies (NAMs).
Contact us for more information.
Read more about our services here:
Medical Devices
Pharmaceuticals
Chemicals